AusBiotech

Australian radiopharmaceutical company Cyclopharm (ASX:CYC) has achieved a significant milestone in its US expansion, with Lucile Packard Children’s Hospital Stanford set to implement Technegas for paediatric lung imaging.

AusBiotech has been named as one of the national peak bodies selected to join the Australian Government’s newly established Trade Diversification Network.

Neuren Pharmaceuticals (ASX:NEU) has entered 2026 with growing confidence in the global trajectory of DAYBUE, its first-in-class treatment for Rett syndrome, as new data and commercial milestones continue to accumulate.

HaemaLogiX has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, marking a significant leadership transition as the company prepares for its next stage of clinical and corporate development.

Radiopharm Theranostics (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, LLC, the company’s joint venture with The University of Texas MD Anderson Cancer Center , from 75 per cent to 87.5 per cent.

CLINUVEL (ASX:CUV) has commenced dosing in a new preclinical study evaluating its proprietary controlled-release liquid injectable peptide formulation, VLRX-L.

In a significant cross-border collaboration, Australian company AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have entered into an agreement with Shanghai Cell Therapy Group to co-develop and commercialise a cutting-edge cancer treatment, BZDS1901, outside China.

Australian biotechnology company Vaxxas has appointed former MSD Global Vaccines President David Peacock as Chief Executive Officer.

Neuren Pharmaceuticals (ASX:NEU) has reached a regulatory milestone with Health Canada approving its Clinical Trial Application for the Koala Phase 3 clinical trial of NNZ-2591, a drug candidate under development for Phelan-McDermid syndrome.

INOVIQ (ASX:IIQ) has reported preclinical evidence supporting the potential of its chimeric antigen receptor exosome technology as a next-generation cancer therapeutic.

Dimerix (ASX:DXB) has found itself at the centre of a significant global rare-disease transaction, following BioMarin Pharmaceutical’s US$4.8 billion acquisition of Amicus Therapeutics, the Australian company’s U.S. commercial licensing partner.

Clarity Pharmaceuticals (ASX:CU6) has taken a step toward regulatory approval of its diagnostic imaging agent, announcing it will commence a pivotal Phase 3 trial of Cu-64 SARTATE in patients with neuroendocrine tumours following positive guidance from the U.S. Food and Drug Administration.